Adverse Event Signal Detection Using Patients' Concerns in Pharmaceutical Care Records: Evaluation of Deep Learning Models

被引:1
作者
Nishioka, Satoshi [1 ]
Watabe, Satoshi [1 ]
Yanagisawa, Yuki [1 ]
Sayama, Kyoko [1 ]
Kizaki, Hayato [1 ]
Imai, Shungo [1 ]
Someya, Mitsuhiro [2 ]
Taniguchi, Ryoo [2 ]
Yada, Shuntaro [3 ]
Aramaki, Eiji [3 ]
Hori, Satoko [1 ]
机构
[1] Keio Univ, Fac Pharm, Div Drug Informat, 1-5-30 Shibakoen,Minato ku, Tokyo 1058512, Japan
[2] Nakajima Pharm, Sapporo, Hokkaido, Japan
[3] Nara Inst Sci & Technol, Nara, Japan
基金
日本科学技术振兴机构; 日本学术振兴会;
关键词
cancer; anticancer drug; adverse event; side effect; patient-reported outcome; patients' voice; patient-oriented; patient narrative; natural language processing; deep learning; pharmaceutical care record; SOAP; FOOT SKIN REACTION; QUALITY-OF-LIFE; PHARMACOVIGILANCE; EXTRACTION; DIAGNOSIS;
D O I
10.2196/55794
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Early detection of adverse events and their management are crucial to improving anticancer treatment outcomes, and listening to patients' subjective opinions (patients' voices) can make a major contribution to improving safety management. Recent progress in deep learning technologies has enabled various new approaches for the evaluation of safety -related events based on patient -generated text data, but few studies have focused on the improvement of real-time safety monitoring for individual patients. In addition, no study has yet been performed to validate deep learning models for screening patients' narratives for clinically important adverse event signals that require medical intervention. In our previous work, novel deep learning models have been developed to detect adverse event signals for hand -foot syndrome or adverse events limiting patients' daily lives from the authored narratives of patients with cancer, aiming ultimately to use them as safety monitoring support tools for individual patients. Objective: This study was designed to evaluate whether our deep learning models can screen clinically important adverse event signals that require intervention by health care professionals. The applicability of our deep learning models to data on patients' concerns at pharmacies was also assessed. Methods: Pharmaceutical care records at community pharmacies were used for the evaluation of our deep learning models. The records followed the SOAP format, consisting of subjective (S), objective (O), assessment (A), and plan (P) columns. Because of the unique combination of patients' concerns in the S column and the professional records of the pharmacists, this was considered a suitable data for the present purpose. Our deep learning models were applied to the S records of patients with cancer, and the extracted adverse event signals were assessed in relation to medical actions and prescribed drugs. Results: From 30,784 S records of 2479 patients with at least 1 prescription of anticancer drugs, our deep learning models extracted true adverse event signals with more than 80% accuracy for both hand -foot syndrome (n=152, 91%) and adverse events limiting patients' daily lives (n=157, 80.1%). The deep learning models were also able to screen adverse event signals that require medical intervention by health care providers. The extracted adverse event signals could reflect the side effects of anticancer drugs used by the patients based on analysis of prescribed anticancer drugs. "Pain or numbness" (n=57, 36.3%), "fever" (n=46, 29.3%), and "nausea" (n=40, 25.5%) were common symptoms out of the true adverse event signals identified by the model for adverse events limiting patients' daily lives. Conclusions: Our deep learning models were able to screen clinically important adverse event signals that require intervention for symptoms. It was also confirmed that these deep learning models could be applied to patients' subjective information recorded in pharmaceutical care records accumulated during pharmacists' daily work.
引用
收藏
页数:17
相关论文
共 60 条
  • [1] Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management
    Ai, Leilei
    Xu, Ziheng
    Yang, Bo
    He, Qiaojun
    Luo, Peihua
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (12) : 1121 - 1127
  • [2] [Anonymous], 2009, The Patient Reported Outcomes Measurement Information System (PROMIS): a walk through the first four years
  • [3] [Anonymous], Global Cancer Observatory
  • [4] [Anonymous], 2016, Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man-the use of patient-reported outcome (PRO) measures in oncology studies-scientific guideline
  • [5] Bartal Alexandra, 2011, Magy Onkol, V55, P91, DOI MagyOnkol.2011.55.2.91
  • [6] The Missing Voice of Patients in Drug-Safety Reporting
    Basch, Ethan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (10) : 865 - 869
  • [7] Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes
    Basch, Ethan
    Jia, Xiaoyu
    Heller, Glenn
    Barz, Allison
    Sit, Laura
    Fruscione, Michael
    Appawu, Mark
    Iasonos, Alexia
    Atkinson, Thomas
    Goldfarb, Shari
    Culkin, Ann
    Kris, Mark G.
    Schrag, Deborah
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (23): : 1624 - 1632
  • [8] Bousquet C, 2017, JMIR RES PROTOC, V6, DOI 10.2196/resprot.6463
  • [9] Patient-reported outcome measures (PROMs): A review of generic and condition-specific measures and a discussion of trends and issues
    Churruca, Kate
    Pomare, Chiara
    Ellis, Louise A.
    Long, Janet C.
    Henderson, Suzanna B.
    Murphy, Lisa E. D.
    Leahy, Christopher J.
    Braithwaite, Jeffrey
    [J]. HEALTH EXPECTATIONS, 2021, 24 (04) : 1015 - 1024
  • [10] Improving Cancer Patient Outcomes and Cost-Effectiveness: A Markov Simulation of Improved Early Detection, Side Effect Management, and Palliative Care
    Cuomo, Raphael E.
    [J]. CANCER INVESTIGATION, 2023, 41 (10) : 858 - 862